Showing results (381-390 of 389) with videos related to
Sort By:
Pageof 39
You have reached the last page of results.This site can display upto 389 results.
Cancer Medicine|May 22, 2023
Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patientsYuka Oku, Gouji Toyokawa, Sho Wakasu, et al.Lung Cancer (Amsterdam, Netherlands)|May 13, 2026
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancerYoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, et al.JTO Clinical and Research Reports|April 23, 2024
The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung AdenocarcinomaHiroaki Kanemura, Toshihide Yokoyama, Ryu Nakajima, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2025
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLCMyung-Ju Ahn, Aaron Lisberg, Yasushi Goto, et al.The Lancet. Respiratory Medicine|August 19, 2024
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trialYoshimasa Shiraishi, Shogo Nomura, Shunichi Sugawara, et al.Science Translational Medicine|September 9, 2011
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabKimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, et al.Nature|November 25, 2021
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancerHiroki Izumi, Shingo Matsumoto, Jie Liu, et al.Respiratory Investigation|August 5, 2019
Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumoniaTakashi Ogura, Nagio Takigawa, Keisuke Tomii, et al.The Journal of Allergy and Clinical Immunology|May 21, 2026
One-Year Clinical Remission with Tezepelumab in Severe Asthma: TERESA Single-Arm Prospective StudyKeiko Kan-O, Hiroko Watanabe, Kenji Chibana, et al.Pageof 39